Posted on 11 月 15, 202311/15/23
Incorporating Medical Science Liaisons Early and Often Amplifies Impact and Delivers Stronger Patient Outcomes
Posted on 10 月 17, 202310/17/23
Utilization of Indirect Treatment Comparison (ITC), External Control Arms (ECA) and Patient-Reported Outcome Measures (PROMs)
Posted on 6 月 16, 20236/16/23
Digital Guide to Commercializing Complex Therapeutics
Posted on 5 月 31, 20235/31/23
Patient-centric Approach to Clinical Trial Support Leveraging Medical Information Services
Posted on 5 月 15, 20235/15/23
Role of Decentralized Trials for Newer Drug Approvals
Posted on 4 月 17, 20234/17/23
What EVERSANA’s Growing Abstract Count at ISPOR U.S. Means to the HEOR Industry
Posted on 11 月 13, 202211/13/22
Establishing the Patient Access Mission During Clinical Development
Posted on 7 月 27, 20227/27/22
EVERSANA’s Continued Commitment to Rare Disease
Posted on 7 月 14, 20217/14/21